CD8A and head and neck squamous cell carcinoma: At this time, both companies are moving forward with next generation TCR-T products incorporating a CD8a coreceptor and affinity optimized TCR [127, 128], OSCC patients may be eligible in future trials given prior interest in HNSCC for MAGE-A4 targeting.